Moderna's stock has soared 650% this year after a few years of weakness, driven by earnings improvements and a focus on oncology and rare disease candidates, though it remains far below its pandemic-era record and trades 60% above analysts' estimates. The article explains that a stock split mechanically lowers the share price in proportion to the ratio without changing a company's valuation, and companies often split after strong gains push prices to high levels. Moderna has not yet done a stock split. The author notes that positive phase 3 results for its personalized cancer vaccine in melanoma, a possible regulatory submission, and about nine additional trials are potential catalysts, so Moderna may not split just yet.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
Modernapharmaceuticalshealthcarevaluationstock split
Open a keyword to see other news on the same topic.
Related news
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
Investors had 'incredibly high' expectations for Phase 3 data on the drugmaker's experimental cancer treatment.
- Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
Moderna shares fell 7% to $185.74 in morning trading after its personalized melanoma vaccine, intismeran autogene, given with Keytruda, met its primary goal of reducing the risk of recurrence or death, but its effect on distant metastasis was far smaller than an earlier mid-stage study suggested. Detailed late-stage results were released on October 22 ahead of a conference in Madrid. BioNTech fell 3% to $85.65, Merck fell 0.2% to $145.61 and Pfizer fell 0.2% to $29.96, while the iShares Biotechnology ETF rose 0.2% to $208.21. The article notes Moderna's business relies entirely on mRNA medicines, so the vaccine carries a large share of its pipeline value, and says the next step is whether the full dataset supports a regulatory filing.
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
The first Phase 3 data for a cancer vaccine has raised doubts about whether the potential treatment is needed. According to the headline, the real test lies in keeping cancer from returning over the long term rather than in beating Keytruda.
- Moderna's Stock Just Stumbled. Is It a Buy on the Dip?
Moderna shares fell 17% in one session after leaked data from a phase 3 trial of intismeran autogene combined with Merck's Keytruda, though the leaked results showed the drug combo cut the risk of recurrence or death by 42% in certain melanoma patients versus Keytruda alone, and by 58% after six months. The stock has still climbed more than 500% this year, trading near $200 versus an average Wall Street 12-month price estimate of $135. The author sees the dip as possibly a buying opportunity for long-term investors who want to open or add to a position, while cautioning that the stock remains sensitive to trial data and may see further pullbacks. Moderna currently has four commercialized products in the U.S., all respiratory vaccines.
- Moderna shares plunge after leak of partial cancer vaccine data despite positive results
Moderna shares fell as much as 25% on Thursday after partial data from its cancer vaccine developed with Merck leaked ahead of the full results, which were released later that day. The full data appeared positive relative to Wall Street expectations: the personalized vaccine intismeran autogene, combined with Keytruda, reduced the risk of recurrence or death in certain melanoma patients by 42% versus Keytruda alone, and cut the risk of distant spread or death by 38%. Detailed phase 3 results will be presented at the European Society for Medical Oncology conference this weekend. Investors view the vaccine as a possible breakthrough that could extend to other cancers, and the stock has spiked more than 530% this year on high expectations.
- Moderna's stock tumbles after reported leak of data for cancer vaccine
Moderna's stock fell following a reported leak of data for its cancer vaccine. Moderna and Merck are expected to share Phase 3 data for their experimental cancer vaccine at a medical conference this weekend.
Related markets
Latest news
- Nvidia stock valuation gets torched by tech stock rout
Nvidia (NVDA) shares trade at a forward P/E of just 12.9 times according to Yahoo Finance AlphaSpace data, versus 18.7 times for the S&P 500, with a PEG ratio of 0.27. The article attributes the selloff to shrinking free cash flow at Alphabet, Meta and Amazon as capex rises sharply, and to concern that hyperscalers may cut capex in 2027, which could mean fewer AI chip orders for Nvidia. On Friday, more than $1 trillion in market value was wiped out and Nvidia finished down 4.22%. Miller Tabak chief markets strategist Matt Maley said “the AI narrative is cracking as profitability concerns intensify.”
- Defense, healthcare, crypto and AI: How the midterm election could affect stocks
Several large U.S. companies depend heavily on Washington: about 70% of Lockheed Martin's sales come from the U.S. government, and Medicaid accounts for three-quarters of Molina Healthcare's premium revenue. A Democratic win in either chamber of Congress would give the party power to investigate companies, challenge federal spending and demand concessions, though President Trump would keep his veto and broad authority over tariffs and regulation. A Morgan Stanley analysis found the S&P 500 gained an average of 23% in the year after midterms under Republican presidents when Congress was split, versus 16% when Democrats controlled both chambers, though some analysts caution against assuming the pattern will repeat. Democrats have already sought records from donors to Trump's White House ballroom, and the 2025 tax and spending law is projected to cut federal Medicaid spending by $911 billion through 2034, a change that could pressure Molina, whose Medicaid revenue reached $32.2 billion in 2025.
- It would shock you how bearish Wall Street is on hyperscalers Microsoft, Amazon, Alphabet, Meta and Oracle
Costco (COST) and Walmart (WMT) trade at forward P/E ratios of 44 and 41 times, above those of hyperscalers Microsoft (MSFT), Amazon (AMZN), Alphabet (GOOG), Meta (META) and Oracle (ORCL). An S&P Global Market Intelligence analysis puts the hyperscalers' average revenue growth at 21% with an average forward P/E of 20.7 times, suggesting the market is paying more for slower-growing companies. The article attributes this to shrinking free cash flow at Big Tech leaders as capex rises sharply, and to concern that hyperscalers may cut capex in 2027. More than $1 trillion in market value was wiped out on Friday. Yorkville Ives partner Dan Ives said it is not the time to panic, citing stronger validation of enterprise AI buildouts, while noting that tech companies raising funds through bonds and equity offerings add pressure.
- Trezor lifts password ceiling after Coldcard’s $100M wallet thefts
Hardware wallet maker Trezor has raised the maximum length of optional passphrases from 50 to 128 characters, available in Trezor Suite with updated firmware, while older firmware still caps passphrases at 50 characters. The change follows the July Coldcard attacks, when a firmware flaw led some devices to generate recovery phrases with insufficient randomness, and strong, unique passphrases protected some affected users. Separately, Trezor advised customers who bought wallets from former reseller CryptoBilis since March to move their funds, after an Indonesian customer reported a suspected implant in a Trezor Safe 5 that could capture recovery phrases; Trezor said it had not examined the device and had received no reports of related losses.
- Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combo
AbbVie's Phase 2 study of ABBV-466, which combines Skyrizi with trosunilimab to target two separate drivers of Crohn's inflammation, met its primary endpoint. At week 24, 40.5% of patients on the combination reached endoscopic remission, versus 22.4% on Skyrizi alone and 20% on trosunilimab alone, while serious adverse events occurred in 10.4% of the combination group, compared with 9.6% for Skyrizi and 9% for trosunilimab. BMO Capital Markets and RBC Capital Markets analysts viewed the results positively. The author, noting that Skyrizi and Rinvoq generated $17.5 billion and $8.3 billion in 2025, predicts ABBV-466 could become AbbVie's next blockbuster, while acknowledging that a Phase 3 program and a multi-year approval path still lie ahead.
- FBI Blames North Korea for $6B Binance Hack as Exchange Reopens Withdrawals
The FBI said North Korea's TraderTraitor was behind the theft of more than $6 billion from Binance and published hundreds of linked addresses. Binance began restoring withdrawals on Sunday, processing $4.649 billion in withdrawals and $1.01 billion in deposits in the first nine and a half hours, a net outflow of about $3.64 billion, or 2.1% of the $171 billion in assets reported in its latest proof of reserves. The FBI said the hackers mainly converted stolen assets into Ethereum and were expected to launder funds through DeFi and instant swap services, urging businesses to block transactions tied to hundreds of Ethereum addresses, 19 Bitcoin addresses and one Solana address. Chainalysis said more than $500 million had moved through Tron, while CEO Richard Teng said Binance had replenished about 95% of affected assets and would absorb the financial impact. According to Reuters, Circle has frozen more than $1.1 billion in USDC.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.